Sacituzumab Govitecan bulk supplier for pharma manufacturers

Sacituzumab Govitecan 180 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 180 mg

Reference Brands: Trodelvy (USA/EU)

Sacituzumab Govitecan is a Oncology Cancer Care product available as Injection in strengths 180 mg. It corresponds to the reference brand Trodelvy (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Sacituzumab Govitecan? List it or send an offer →

Product Description:

Sacituzumab govitecan is a targeted anticancer medicine used for the treatment of certain advanced or metastatic cancers. It is an antibody–drug conjugate designed to deliver chemotherapy directly to cancer cells. The drug consists of a monoclonal antibody that targets the Trop-2 protein, which is commonly found on the surface of many tumor cells, combined with a topoisomerase inhibitor that helps destroy cancer cells. By binding to Trop-2 and releasing the cytotoxic agent inside the tumor, sacituzumab govitecan helps reduce tumor growth while focusing treatment on cancer cells.

This therapy is used in patients with metastatic triple-negative breast cancer who have previously received other treatments. It is also approved for patients with metastatic hormone receptor-positive, HER2-negative breast cancer that has progressed after prior therapies. In addition, sacituzumab govitecan is used in certain cases of metastatic urothelial cancer when other treatment options have been used.

Because of its targeted delivery system, sacituzumab govitecan represents an important advancement in modern oncology treatments. It provides an additional option for patients with difficult-to-treat cancers and helps improve disease management in advanced stages of these conditions.

Sacituzumab Govitecan — third party manufacturing & bulk supply

Sacituzumab Govitecan 180 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Sacituzumab Govitecan is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Sacituzumab Govitecan listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Sacituzumab Govitecan →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Sacituzumab govitecan-hziy is used for the treatment of certain advanced or metastatic cancers, particularly triple-negative breast cancer (TNBC) and some cases of hormone receptor-positive, HER2-negative breast cancer that have progressed after prior therapies. It is also used in certain cases of advanced urothelial (bladder) cancer.

Sacituzumab govitecan-hziy is an antibody–drug conjugate that combines a monoclonal antibody targeting the Trop-2 protein with a cytotoxic chemotherapy agent. This design allows the drug to deliver chemotherapy directly to cancer cells that express the Trop-2 antigen.

The primary trade name of Sacituzumab govitecan-hziy is Trodelvy.

Sacituzumab govitecan-hziy (Trodelvy) is developed and marketed by Gilead Sciences.

The generic name is Sacituzumab govitecan-hziy.

The main brand name is Trodelvy.

Sacituzumab govitecan-hziy is manufactured in GMP-certified biologics production facilities approved by major regulatory authorities such as the US FDA, EMA, and other international health agencies depending on the market where it is supplied.